According to Oragenics, Canadian biopharmaceutical research consortium CQDM has awarded a grant for development of variant-agnostic protein antigens for use in an intranasal COVID-19 vaccine that "aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1." According to the CQDM web site, the total value of the project is $1.64 million, with … [Read more...] about CQDM provides funding for Oragenics intranasal COVID-19 vaccine
Business
Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients
Pneumagen said that it has closed an £8 million funding round, with proceeds going to support Phase 2 development of the company's Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, including a Phase 2b trial in COPD patients experiencing exacerbations caused by viral infection that is expected to be initiated in 2024. The company announced in … [Read more...] about Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients
Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials
Nephron Pharmaceuticals announced that the company is now offering 0.5% albuterol sulfate inhalation solution in 5 ml vials for direct shipping to US medical facilities in response to a nationwide shortage. Ritedose Pharmaceuticals recently announced that if would begin manufacturing 0.5% albuterol in response to the shortage. Nephron notes that has been manufacturing … [Read more...] about Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials
Pulmotect gets $8.9 million grant for Phase 2 trial of PUL-042 inhalation solution
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded an $8.9 million grant to Pulmotect for continued development of the company's PUL-042 immune stimulating inhalation solution, the company announced. Pulmotect said that the funds will go toward a Phase 2 trial titled, “A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 … [Read more...] about Pulmotect gets $8.9 million grant for Phase 2 trial of PUL-042 inhalation solution
Aerami says it will advance AER-901 inhaled imatinib into a Phase 2 trial for PAH and PH-ILD
Aerami Therapeutics said that pre-clinical and Phase 1 data presented recently at ATS support advancing the company's AER-901 nebulized imatinib into a Phase 2 trial that will include both patients with pulmonary arterial hypertension (PAH) and patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company said that it expects to … [Read more...] about Aerami says it will advance AER-901 inhaled imatinib into a Phase 2 trial for PAH and PH-ILD
Halo Therapeutics raises £1.5 million for Phase 1 trial of its pan-coronavirus antiviral nasal spray
Bristol University spinout Halo Therapeutics announced that it has raised £1.5 million in a funding round led by the Development Bank of Wales to support a Phase 1 trial of the company's HTLX-1 linoleic acid pan-coronavirus antiviral nasal spray. According to the company's web site, Halo is developing nasal formulations based on its free fatty acid technology for both … [Read more...] about Halo Therapeutics raises £1.5 million for Phase 1 trial of its pan-coronavirus antiviral nasal spray
SoftOx Solutions outsources development of SIS inhalation solution to the University of Copenhagen
SoftOx Solutions has announced a restructuring plan that includes shutting down its own GMP facility, laying off employees, and outsourcing further development of its SoftOx inhalation solution (SIS) to the University of Copenhagen. The company said that it would retain ownership of the IP and the commercial rights. In May 2022, SoftOx announced Phase 1 results … [Read more...] about SoftOx Solutions outsources development of SIS inhalation solution to the University of Copenhagen
Lumen Bioscience to develop antiviral intranasal powder for US Department of Defense
Lumen Bioscience said that it has received a contract worth $8.8 million from the Defense Innovation Unit (DIU) of the US Department of Defense for development of "a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention of known and emerging viral respiratory infections." The funding is part of "Project Panacea," run by DIU and the Joint … [Read more...] about Lumen Bioscience to develop antiviral intranasal powder for US Department of Defense
Chance Pharmaceuticals acquires rights to distribute Inbrija levodopa DPI in China
Hangzhou Chance Pharmaceuticals will pay Acorda Therapeutics $2.5 million up front for distribution rights to Inbrija levodopa DPI in China plus another $6 million in "a near term milestone payment" as well as $3 million on approval and as much as $132.5 million in sales milestones. Chance will also pay by the carton for Acorda to supply Inbrija to the company. Acorda … [Read more...] about Chance Pharmaceuticals acquires rights to distribute Inbrija levodopa DPI in China
Strides and Orbicular partner on development of nasal sprays
Generics manufacturer Strides Pharma Science and CRO Orbicular Pharmaceutical Technologies, both based in India, have announced a new strategic partnership where Orbicular will formulate 4 nasal sprays to be manufactured and commercialized by Strides. According to the announcement, Strides will manufacture the nasal sprays at its facility in Chestnut Ridge, NY, USA … [Read more...] about Strides and Orbicular partner on development of nasal sprays